FDA Home Page | Search FDASite | FDA A

- Z Index| Contact FDA

Statement of Norris Alderson, Ph.D. Director, Office of Science and Health Coordination Food and Drug Administration U.S. Department of Health and Human Service

before Committee on Oversight and Government Reform Subcommittee on Domestic Policy House of Representatives

November 14, 2007 

### Introduction

Mr. Chairman and Members of the Subcommi ttee, I am Dr. Norris Alderson, Director, Office of Science and Health Coordination at the Food and Drug Admini stration (FDA or the Agency). I ap preciate your invitation and the opportunity to discuss the issue of dental amalgams and FDA’s implementation of the National Environmental Policy Act of 1969.

In my testimony today, I will first briefly describe dent al amalgam and how FDA regulat es these medical devices. Then, I will describe Federal governm ent activities related to dental am algam. I will also describe FDA’s implementation of the National Environmental Poli cy Act of 1969 with respect to dental amalgam.


### Background

Dental amalgam is a restorative material that is used fo r direct filling of carious lesio ns or structural defects in teeth. It is made onsite in a dentist’s office by mixing elemental (liquid) mercury and a powdered (amalgam) alloy composed primarily of silver, tin, and copper (the mixture is also called "encapsulated amalgam alloy and dental mercury" or simply " encapsulated amalgam").

Let me begin with a brief overview ofour regulatory authorit ies regarding medical devices and how we exercise them in the case of dental amalgam. As defined by F ederal law, the term “medical device” encompasses several thousand health products, from simple articles such as tongue depressors and heating pads, to cutting-edge and complex devices such as pacemaker s, lasers and imaging technologies. D ental amalgam, as well as its components – dental mercury and the alloy with which the mercury is combined – are medical devices. The Medical Device Amendments of 1976 to the Federal Food, Drug, and Cosmetic Act (F D&C Act or the Act) gave FDA specific authority to regulate the safety and effect iveness of medical devices. T he FD&C Act prescribes a variety of mechanisms to achieve this goal. These inc lude classification of medic al devices, establishment registration, Quality Systems Requirem ents for manufacturing, and controls over the market introduction of medical devices.



### Classification and Reclassification of Medical Devices

Devices that were in commercial distribution before the enactment of the Medical Device Amendments of 1976 (May 28, 1976), are commonly referred to as “pream endments devices” and were assigned to one of three “classes” consistent with the procedures described in th e statute. Under section 513 of the Act, FDA classifies preamendments devices according to the following steps: (1) FDA rece ives a recommendation from a device classification panel (an FDA advisory committee); (2 ) FDA publishes the panel’s recommendation for comment, along with a proposed regulation classi fying the device; and (3) FDA publishes a final regulation. The Act also has a specific procedure for effecting a change to the c lassification of a preamendm ents device, which includes issuing a regulation (section 513(e) of the Act) and , if the Agency believes appropriate, obtaining a recommendation from the panel that prov ided the original classification recommendation. Devices that were first introduced into commercial distribution after enactment of the Medica l Device Amendments Act of 1976, are known as “postamendments devices.”

Let me describe the statutory criteria FDA used when clas sifying medical devices. Devi ces posing the lowest risk, such as elastic bandages, were placed in Class I. Class I devices are subject to the “general controls” applicable to all devices. Class II devices, whic h pose incrementally greater risk a nd for which general controls are not sufficient to provide reasonable assurance of safety and e ffectiveness, are subject to “s pecial controls” in addition to general controls. Special controls may include labeli ng requirements, performanc e standards, post-market surveillance studies to conformance with mandatory performance standards, or other cont rols the Agency deems necessary to provide reasonabl e assurance of the safety and effectivene ss of the device. The riskiest devices, such as some implants and life-supporting or life-sust aining devices, are placed in Class III and may be marketed 

# Page 1 of 3 Statement of Norris Alderson, Ph.D., Director , Office of Science and Health Coordination

7/3/2008 http ://www.fda. g ov/ola/2007/dentalmercury 111407.htmlonly after approval of a premarket approval applicati on, which includes clinical st udies and other information establishing the safety and effectiveness of the device. Preamendments devices classi fied into Class III are not subject to the requirement of premar ket approval until the Agency issues a regulation requiring the submission of applications.

Dental mercury and amalgam alloy are preamendments dev ices that FDA classified in accordance with the procedure described above. In a Final Rule published on August 12, 1987, FDA placed dental mercury into Class I (Title 21, Code of Federal Regulations , section 872.3700) and amalgam alloy into Class II (Title 21, Code of Federal Regulations , section 872.3050). This action was taken because comments submitted to the Agency acknowledged that the risks to health presented to dentists and other dental workers are inherent in the device and would not be reduced through establishment of perf ormance standards for the device. The comments also stated that manufacturers have vol untarily accomplished actions to protect dentists and others from the inherent risks presented by the device such as packaging the device in leak proof containers and placing cautionary statements in the labeling of the device. FDA agreed with the comments urging that dental mercury be classified into Class I. The encapsulated form of amalgam, which consists of measured proportions of amalgam alloy and dental mercury that are separately s ealed and sold as a single-use capsule, was not separately classified during the original classification process. However, like other products that are a combination of more than one device, FDA has regulated the encapsulated amalgam in accord ance with the requirements applicable to the component with the higher classification. Accordingly, the encapsulat ed form of amalgam (which includes amalgam alloy and dental mercury) is regulated as a Class II device.

The Dental Products Panel of the Medical Devices Ad visory Committee met in 1993 and 1994 to discuss the classification, reclassification and safety of dental amalgam devices. After cons idering testimony and other information, the Panel unanimously recommended to classi fy dental mercury and amalgam alloy intended for the restoration of teeth into Class II. The Panel also recommended that the device be subject to voluntary performance standards, voluntary testing guidelines, and requirements that th e device be used only on the written or oral authorization of a licensed practitioner, and only by persons with training or expertise in its use. The Panel stated that there were no major risks associated wi th encapsulated amalgam w hen used as directed, but recognized there was a small population of patients who ma y experience allergic reactions to the materials in the device. The Panel also noted that improper use of the dev ice by practitioners present ed risks associated with mercury toxicity.

As mentioned earlier, the FD&C Act authorizes the Agency to “reclassify” a medical device into a different regulatory class as more knowledge emerges regarding product ri sk gained from actual use. In most cases, devices are down-classified. Occasionally, however, devices are reclassified into a higher class.


### 2002 Proposed Rule Reclassifying Amalgam Products

In February 2002, FDA proposed a rule to bring all am algam products into Class II and increase the Agency’s regulatory oversight over these devices by requi ring ingredient labeling and pr oposing conformance to international standards. By requiring di sclosure of amalgam ingredients, t he Agency believed the rule would help dental providers to quickly diagnose and treat rare al lergic reactions arising from exposure to amalgam components. Given the high level of interest in this proposed rule, FDA twice reopened the comment period and received more than 750 comments submitted to the docket.

FDA received significant adverse publiccomments on the 2002 proposed r ule. The majority of the comments stated that the Agency was not proposing enough re strictions on the marketing and use of dental amalgam and that the proposed special controls did not adequat ely address the potential health risks of the device.


### Dental Amalgam Literature Reviews

In January 1993, the United States Public Health Service (USPHS) published a broad sc ientific report about the safety and use of dental amalgam and other materials commonly used to fill dental cavities. USPHS reaffirmed these conclusions in 1995 and 1997. Since then, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and FDA have continued to study the issue. The National Institute of Dental & Craniofacial Research at NIH has also provided grants to study the safety of dental amalgam and to develop nonmercury alternatives. This effort in cluded research and clinical studies of dental amalgam use in children. In addition, USPHS scientists analyzed approximately 175 peer-reviewed studie s submitted in support of three citizen petitions received by FDA after the 1993 report. The USPHS concluded that data in these studies did not support claims that individuals with dental amalgam restorations will experience problems, including neurologic, renal or developmental effects, except for ra re allergic or hypersensitivity reactions.


### 2006 Joint Meeting of the Dental Products Panel and the Peripheral and Central Nervous System Drugs Advisory Committee

In 2006, FDA held a joint meeting of the Dental Products Panel and the Peripheral and Central Nervous System Drugs Advisory Committee. The joint committee deliberat ed on a series of questions FDA had posed on its most recent draft review of the dental amalgam literature , and provided recommendations to the Agency related to those questions. The Committee asked FDA to expand its literature review to include additional data bases and searches for information on special populations. The 2006 jo int committee generally agreed, however, that there is no evidence that dental amalgam cause health problems in the vast majority of the population. The 2006 joint committee also agreed that the most recent well-controlled clinical studi es showed no evidence of neurological harm from dental amalgam. While the committee did not take consensus votes on these issues, non consensus 

# Page 2 of 3 Statement of Norris Alderson, Ph.D., Director , Office of Science and Health Coordination

7/3/2008 http ://www.fda. g ov/ola/2007/dentalmercury 111407.htmlopinions included a panelist recommendation that FDA cons ider labeling requirements related to the use of dental amalgam in pregnant women and small children, as well as patient information to ensure that consumers understand that these dev ices contain mercury.


### The National Environmental Policy Act (NEPA)

The National Environmental Policy Act of 1969 (NEPA) requires that Federal agencie s evaluate whether major actions they take will significantly affect the qualit y of the human environment. FDA’s regulations implementing NEPA are contained in 21 CFR Part 25, “Environmental Impact Considerations.” This regulation describes Agency actions that require preparation ofan Environmental Assessment (EA), that require preparation of an Environmental Impact Statement (EIS), and those Agency actions that are categorically ex cluded, generally, from the requirement to prepare and EA or an EIS absent ex traordinary circumstances. Actions are categorically excluded from the requirement to pr epare an EA or an EIS where the Agency has made a finding that the category of action does not individually or cum ulatively have a significant effect on the human environment. If the Agency finds that a particular action, that w ould otherwise be categorical ly excluded, may significantly affect the quality of the human environment (referred to as an "extraordinary circumst ance"), the Agency would prepare either an EA or an EIS. It should be clarified that the analysis is det ermined by the action taken bythe Agency, and not the product in question. FDA has no reason to think that changing t he classification of mercury, by itself, will affect its level of use, e.g., either increase ordecrease, in a way that would have a significant effect on the environment.

In the case of a classification of dental amalgam, reclas sifying dental mercury from Cl ass I to Class II does not necessarily affect the amount of mercury introduced into the environment. If it is not reasonably foreseeable that there would be any increase in the amount of mercury int roduced into the environment that would constitute an extraordinary circumstanc e, FDA would appropriately rely on its exist ing categorical exclusion for such an action. The 2002 Proposed Rule noted above cited the ca tegorical exclusion contained in Title 21, Code of Federal Regulations section 25.34(b), which categorically exc luded the classification or reclassification of a device from the requirement to prepare an EA.


### Next Steps/Options

We will continue to evaluate the available information to determine appropriate next steps to fulfill FDA’s mission to protect and promote public health.

Mr. Chairman, thank you again for the opportunity to address this important topic. I will be happy to answer any questions.

Getfree weekly updates about FDA press releases, recall s, speeches, testimony and more.

Other Recent Testimony

FDA Home Page | Search FDA Site | FDA A

- Z Index| Contact FDA | Privacy| Accessibility

FDA Office of Legislation 

# Page 3 of 3 Statement of Norris Alderson, Ph.D., Director , Office of Science and Health Coordination

7/3/2008 http ://www.fda. g ov/ola/2007/dentalmercury 111407.html